Literature DB >> 10434296

Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease.

J H Cha1, A S Frey, S A Alsdorf, J A Kerner, C M Kosinski, L Mangiarini, J B Penney, S W Davies, G P Bates, A B Young.   

Abstract

Alterations in neurotransmitter receptors are a pathological hallmark of the neurodegeneration seen in Huntington's disease (HD). However, the significance of these alterations has been uncertain, possibly reflecting simply the loss of brain cells. It is not known for certain whether the alteration of neurotransmitter receptors occurs before the onset of symptoms in human HD. Recently we developed transgenic mice that contain a portion of a human HD gene and develop a progressive abnormal neurological phenotype. Neurotransmitter receptors that are altered in HD (receptors for glutamate, dopamine, acetylcholine and adenosine) are decreased in the brain transgenic mice, in some cases before the onset of behavioural or motor symptoms. In transgenic mice, neurotransmitter receptor alterations occur before neuronal death. Further, receptor alterations are selective in that certain receptors, namely N-methyl-D-aspartate and gamma-aminobutyric acid receptors, are unaltered. Finally, receptor decreases are preceded by selective decreases in the corresponding mRNA species, suggesting the altered transcription of specific genes. These results suggest that (i) receptor decreases precede, and therefore might contribute to, the development of clinical symptoms, and (ii) altered transcription of specific genes might be a key pathological mechanism in HD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10434296      PMCID: PMC1692608          DOI: 10.1098/rstb.1999.0449

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  45 in total

1.  Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study.

Authors:  S J Augood; R L Faull; D R Love; P C Emson
Journal:  Neuroscience       Date:  1996-06       Impact factor: 3.590

2.  Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease.

Authors:  L S Dure; A B Young; J B Penney
Journal:  Ann Neurol       Date:  1991-12       Impact factor: 10.422

3.  Glutamate receptor expression in rat striatum: effect of deafferentation.

Authors:  U Wüllner; D G Standaert; C M Testa; G B Landwehrmeyer; M V Catania; J B Penney; A B Young
Journal:  Brain Res       Date:  1994-06-06       Impact factor: 3.252

4.  The distribution of GABAA-benzodiazepine receptors in the basal ganglia in Huntington's disease and in the quinolinic acid-lesioned rat.

Authors:  R L Faull; H J Waldvogel; L F Nicholson; B J Synek
Journal:  Prog Brain Res       Date:  1993       Impact factor: 2.453

5.  Quisqualate resolves two distinct metabotropic [3H]glutamate binding sites.

Authors:  M V Catania; Z Hollingsworth; J B Penney; A B Young
Journal:  Neuroreport       Date:  1993-03       Impact factor: 1.837

6.  Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases.

Authors:  M F Perutz; T Johnson; M Suzuki; J T Finch
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

7.  Multiple states of rat brain (RS)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors as revealed by quantitative autoradiography.

Authors:  J H Cha; R L Makowiec; J B Penney; A B Young
Journal:  Mol Pharmacol       Date:  1992-05       Impact factor: 4.436

8.  Neuropathological classification of Huntington's disease.

Authors:  J P Vonsattel; R H Myers; T J Stevens; R J Ferrante; E D Bird; E P Richardson
Journal:  J Neuropathol Exp Neurol       Date:  1985-11       Impact factor: 3.685

9.  Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease.

Authors:  R A Weeks; P Piccini; A E Harding; D J Brooks
Journal:  Ann Neurol       Date:  1996-07       Impact factor: 10.422

10.  Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons.

Authors:  M DiFiglia; E Sapp; K Chase; C Schwarz; A Meloni; C Young; E Martin; J P Vonsattel; R Carraway; S A Reeves
Journal:  Neuron       Date:  1995-05       Impact factor: 17.173

View more
  42 in total

1.  Modeling Huntington's disease in cells, flies, and mice.

Authors:  S Sipione; E Cattaneo
Journal:  Mol Neurobiol       Date:  2001-02       Impact factor: 5.590

2.  Allele-specific conditional destabilization of glutamine repeat mRNAs.

Authors:  Andrew B Crouse; Peter J Detloff
Journal:  Gene Expr       Date:  2005

Review 3.  Brain networks in Huntington disease.

Authors:  David Eidelberg; D James Surmeier
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

Review 4.  The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration.

Authors:  Julie Leegwater-Kim; Jang-Ho J Cha
Journal:  NeuroRx       Date:  2004-01

Review 5.  The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease.

Authors:  David Blum; Yijuang Chern; Maria Rosaria Domenici; Luc Buée; Chien-Yu Lin; William Rea; Sergi Ferré; Patrizia Popoli
Journal:  J Caffeine Adenosine Res       Date:  2018-06-01

6.  Changes in striatal procedural memory coding correlate with learning deficits in a mouse model of Huntington disease.

Authors:  Sebastien Cayzac; Sebastien Delcasso; Vietminh Paz; Yannick Jeantet; Yoon H Cho
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-16       Impact factor: 11.205

7.  Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease.

Authors:  Izaskun Villar-Menéndez; Marta Blanch; Shiraz Tyebji; Thais Pereira-Veiga; José Luis Albasanz; Mairena Martín; Isidre Ferrer; Esther Pérez-Navarro; Marta Barrachina
Journal:  Neuromolecular Med       Date:  2013-02-06       Impact factor: 3.843

8.  Monitoring Huntington's disease progression through preclinical and early stages.

Authors:  Chris Tang; Andrew Feigin
Journal:  Neurodegener Dis Manag       Date:  2012-08-01

9.  Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease.

Authors:  C Dirk Keene; Cecilia M P Rodrigues; Tacjana Eich; Manik S Chhabra; Clifford J Steer; Walter C Low
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

10.  Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease.

Authors:  A Vinuela; P J Hallett; C Reske-Nielsen; M Patterson; T D Sotnikova; M G Caron; R R Gainetdinov; O Isacson
Journal:  Brain       Date:  2008-11-06       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.